摘要
目的探讨CYP2B6 Q172H和K262R基因多态性与乳腺癌环磷酰胺类药物辅助化疗预后的关系。方法 100例确诊的乳腺癌患者,采用环磷酰胺类药物为主的方案进行辅助化疗;用聚合酶链反应-连接酶检测反应检测CYP2B6 Q172H和K262R基因多态。结果 100例乳腺癌患者中,携带Q172H(516G>T)GG、GT和TT基因型的患者分别占59%、38%和3%;携带K262R(785A>G)AA、AG和GG基因型的分别占47%、43%和10%。携带Q172HGT和TT基因型的患者无复发生存率显著高于携带GG基因型的患者(P<0.05);携带K262RAG和GG基因型的患者无复发生存率显著高于携带AA基因型的患者。多因素分析结果显示,Q172H多态是影响患者复发的独立危险因素(P<0.05)。结论 Q172HGT和TT基因多态与接受环磷酰胺药物辅助化疗的乳腺癌患者的预后有关。
Objective To investigate the association of CYP2B6 Q172H and K262R polymorphisms with clinical outcome of breast cancer patients treated with cyclophosphamide-based adjuvant chemotherapy.Methods A total of 100 patients with breast cancer were recruited.All patients received cyclophosphamide-based adjuvant chemotherapy.PCR-LDR （ligation detection reaction） method was used to detect genotypes of CYP2B6 Q172H and K262R.Results Of the 100 patients,the prevalence of the Q172H（516GT） GG,GT and TT genotype was 59%,38% and 3%,respectively,and the frequencies of K262R（785AG） AA,AG and GG genotype was 47%,43% and 10%,respectively.The recurrence-free survival rate in patients with Q172H GT and TT genotype were significantly higher than those in patient s with GG genotype （P0.05）.Also,the recurrence-free survival rate in patient s with K262R AG and GG genotype were significantly higher than those in patient s with AA genotype （P0.05）.However,multivariable analysis showed that only Q172H GT and TT genotype were associated with shorter recurrence-free survival （P0.05）.Conclusion Polymorphism of Q172H GT and TT may be a potential prognostic factor in breast cancer patients treated with cyclophosphamide-based adjuvant chemotherapy.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2010年第12期1387-1390,共4页
Cancer Research on Prevention and Treatment
基金
无锡市科技局社会发展计划(CSE00708)
无锡市科技局科技发展计划(333工程)(CAE00801-08)
